The pharmacokinetics and pharmacodynamics of eltrombopag, a thrombopoietin receptor agonist developed for idiopathic thrombocytopenic purpura, were investigated in healthy Japanese adult males after single and repeat doses of eltrombopag in two clinical studies.
Introduction
Eltrombopag olamine is a bis-monoethanolamine salt of eltrombopag, which is a thrombopoietin(TPO) receptor agonist developed by GlaxoSmithKline( Fig.  1 ). It is a low molecular weight compound available for oral administration. Eltrombopag induces proliferation and differentiation of the megakaryocytic lineage cells by activating a part of the TPO signaling pathway through a specific interaction with human TPO receptor and increases in platelet count result 1) .
The thrombopoietic effect of eltrombopag is speciesspecific and seen only in humans and chimpanzees 1, 2) .
From these results, eltrombopag is expected to increase platelet count in various diseases causing thrombocytopenia including idiopathic thrombocyto-penic purpura(ITP). Clinical development of eltrombopag targeting chronic ITP, an autoimmune disease with enhanced platelet destruction and suppression of ／ megakaryopoiesis／thrombopoiesis by an immune reaction with autoantibody against platelets 3, 4) , has been performed.
In healthy non-Japanese adults, repeat doses of eltrombopag B30 mg were reported to increase platelet count 2) . Also in non-Japanese ITP patients, a dose-response study was conducted at the doses of 30, 50 and 75 mg once daily, and significant efficacy was seen with 50 mg and 75 mg doses compared with placebo 5) .
Patients showing no response to eradication of H. pylori or H. pylori-negative patients are treated with a corticosteroid followed by splenectomy(first-line therapy). However, there are cases where these firstline therapies cannot be adopted or intractable cases where the first-line therapies are not sufficiently effective. In such cases, an adequate platelet count cannot be maintained and the risk of hemorrhage and death increases 7) . Immunosuppressive therapy or high-dose steroid therapy is used as a second-line therapy, although such therapies are not considered to be based on sufficient evidence and are accompanied by specific adverse reactions 6, 8) . As drugs which potentially increase platelet count in intractable ITP patients, TPO receptor agonists including eltrombopag are anticipated to be a new therapeutic option. As a TPO receptor agonist, romiplostim, once weekly injection, has recently been approved for ITP in countries including the United States 9) . Eltrombopag to be administered orally once daily is expected to contribute to the treatment of the disease.
In the studies described in the present report, eltrombopag was orally administered as single doses of 30-100 mg and as single and repeat doses of 25-75 mg to healthy Japanese adult males to investigate the pharmacokinetics, safety and effect on platelet count. The present paper reports the results and discusses the relationships between dose and exposure and between dose and changes in platelet count in healthy Japanese adults that are different from those previously reported in healthy non-Japanese subjects.
Study Methods
The studies were conducted at Osaki Clinic(Medical Co., LTA., Tokyo, Japan)in compliance with the Declaration of Helsinki(South Africa, 1996), the Good Clinical Practice(GCP)and the relevant provisions of the Pharmaceutical Affairs Law of Japan after obtaining approval from the IRB of Medical Co., LTA. Written informed consent was obtained from each subject.
ઃ．Study drug
Film-coated tablets containing 5 mg and 25 mg of eltrombopag as eltrombopag olamine, and corresponding placebo tablets were used in Study A. Film-coated tablets containing 25 mg eltrombopag as eltrombopag olamine and corresponding placebo tablets were used in Study B. For Study A, laboratory tests, vital sign determination and 12-lead electrocardiography were performed for safety evaluation up to 72 hours after each single dose and for Study B, these safety data were collected throughout the dosing period and up to 8 days after the last dose.
અ．Determination method and data analysis

Pharmacokinetics
The eltrombopag concentrations in plasma and urine were determined using a validated liquid ／ chromatography mass spectrometry(LC／MS-MS method). The lower limit of quantification(LLQ)was ／ 10 ng／mL. Pharmacokinetic parameters(Cmax, tmax, t1/2, AUC0−24, AUC0−last, AUC0−∞, proportion AUC0−∞ ／ extrapolated(％ AUCex)and CL／F)were calculated from the plasma eltrombopag concentrations and actual sampling times with standard noncompartmental methods using WinNonlin Professional Ver. 3.1(Pharsight Corp., Mountain View, CA, US)in both studies. AUC was calculated using the log-linear trapezoidal rule.
In Study B, in addition to the above, Rs(AUC0−24 on ／ Day 10 of repeat dose／AUC0−∞ of single dose)and ／ RCmax(Cmax on Day 10 of repeat dose／Cmax of single dose)were calculated as accumulation indices.
Statistical analysis of pharmacokinetics
In Study A, to investigate the linearity of exposure after single doses of 30-100 mg, the slope versus dose was calculated using a power model using Windows SAS Ver. 6.12(SAS Institute, Cary, NC, USA).
In Study B, attainment of steady state was assessed by calculation of the slope of log transformed trough concentrations on Days 8, 9 and 10 versus study day using Solaris SAS Ver. 8.2(SAS Institute, Cary, NC, USA).
Pharmacodynamics
Platelet count was determined with an automatic blood cell counter(direct current detection method).
In Study B, for evaluation of platelet count changes after starting repeat dosing, the following pharmacodynamic parameters were calculated using WinNonlin Professional Ver. 3.1；time of maximum platelet count(Platelet-Tmax), maximum platelet count (Platelet-max)and area under the platelet count-time curve(Platelet-AUC). Additionally, the absolute change(b)and percent change(％)after starting repeat dosing were calculated for each time point using the pre-dose platelet count (P0) as baseline value.
In order to investigate the change in platelet aggregation after repeat dosing, adenosine diphosphate(ADP)as an aggregation-inducing substance was added to platelet-rich plasma obtained by centrifugation of whole blood, and the light transmittance determined with a laser light-scattering platelet aggregometer(PA-200, Kowa company. Ltd., Nagoya, Japan).
Results
ઃ．Pharmacokinetics after single and repeat doses Study A
The pharmacokinetic parameters after administration of single oral doses of eltrombopag in the fasted state in Study A are given in Table 1 .
In Study A, the pharmacokinetics after single doses of 30, 50, 75 and 100 mg was investigated in 16 healthy Japanese adult males aged 20-33 years(25.9 years on average)and weighing 55.5-69.6 kg(61.3 kg on average). Plasma eltrombopag concentrations reached a maximum at 3-4 hours(median value) after dosing for all doses. Overall the results are considered generally consistent with a proportional increase in exposure with dose 10) ( Fig. 2 ). In addition, an analysis using the power model showed the slope for AUC0−∞ was 1.11(1.03, 1.20)where the lower limit of the 90％ confidence interval(CI)was slightly greater than 1, but the slope (90％ CI) was 1.02 (0.93, 1.11)for Cmax and 1.07(0.99, 1.15)for AUC0−last, indicating a proportional increase in exposure with dose.
The mean elimination half life calculated from plasma eltrombopag concentration determined up to 72 hours after dosing was in the range of 23-28 hours for all doses. By sampling up to 72 hours after administration, the proportion of AUC0−∞ extrapolated following doses of 50 mg or greater was 13-14％ on average, and exceeded 20％ in 1 subject at each of 50 and 75 mg and in 2 subjects at 100 mg.
Urinary eltrombopag concentrations were also determined. The greatest individual proportion of the dose excreted in urine was 0.032％ and in other subjects all concentrations were below the level of quantitation.
Study B
In Study B, based on the results of Study A, blood samples were taken up to 120 hours after both the single dose and the last dose in the repeat dose phase for calculation of pharmacokinetic parameters.
The pharmacokinetics after single and 10 days repeat doses of 25, 50 and 75 mg administered in the fasted state was investigated in 42 healthy Japanese adult males aged 20-34 years(25.6 years in average) and weighing 55.8-82.0 kg(63.6 kg in average). The demographic factors were comparable among the groups.
The pharmacokinetic parameters obtained in Study B are given in Table 2 , and the mean plasma eltrombopag concentration time profiles are shown in Figure 3 .
After single and repeat doses of 25-75 mg in the fasted state, maximum plasma eltrombopag concentrations were reached at 3-4 hours(median value) after dosing for all doses, as in Study A. Cmax and AUC0−∞ values after single doses were slightly lower than those observed in Study A( Table 2 ). The exposure(Cmax and AUC)after single and repeat doses increased approximately in proportion to dose (Fig. 2) . The elimination half life after single doses and repeat doses were 30-32 hours and 40-50 hours, respectively. The elimination half life after single doses was slightly longer as compared with Study A. The proportion of AUC0−∞ extrapolated after single doses was less than 10％ in all subjects. The steady state ratio after 10 days repeat doses of eltrombopag 25-75 mg, i.e., Rs(AUC0−24 on Day 10 of ／ repeat dose／AUC0−∞ after single dose), was in the range of 1.1-1.2. The 90％ CI for the mean Rs values included unity for the 25 and 50 mg doses and marginally excluded unity for the 75 mg dose, suggesting that the pharmacokinetics of eltrombopag is generally linear and time-invariant( Table 2 ).
Visual check indicated that steady state was reached within 7 days after starting dosing(Day 8) (Fig. 3 ). The slope(90％ CI)of log trough concentration on Days 8, 9 and 10 versus study day was 0.96(0.78, 1.18)for the 25-mg group, 1.06(0.95, 1.19)for the 50-mg group and 1.00(0.91, 1.10)for the 75-mg group. The 90％ CI included 1, which also indicated that the slope was zero and that steady state had been attained.
．Pharmacodynamics after single and repeat doses No significant changes in platelet count were observed after single oral doses of eltrombopag 30-100 mg in Study A. In Study B, no significant changes in platelet count were observed after single oral doses of eltrombopag 25-75 mg. However, after 10-days repeat doses of eltrombopag 25, 50 or 75 mg, increases in platelet count were seen at all dose levels. The increases in platelet count from baseline(％ change of Platelet-max)after 10-days repeat dosing were 54％ in the 25-mg group, 72％ in the 50-mg group and 90％ in the 75-mg group, indicating a dosedependent increase. The baseline platelet counts in the healthy Japanese were similar across all groups and consistent with expectations in this population ( Table 3) .
The platelet count after 10-days repeat dosing reached the maximum 4-6 days after the last dose ／ and returned to the reference range(13.1-36.2×10 4 ／ mL)within 16 days after the last dose in almost all the subjects (Fig. 4 , Table 3 ). However, in 1 subject administered 25 mg, it took 64 days for the platelet count to return to the reference range. In this subject, the platelet count increased from the baseline level of ／ ／ 32.3×10 4 ／mL to the maximum of 59.8×10 4 ／mL 4 days after the last dose.
Platelet function as measured by platelet aggregation was not notably affected by the administration of either eltrombopag or placebo.
The relationship between the increase in platelet count and the exposure(AUC0−24)after 10-days repeat dosing with eltrombopag 25-75 mg was investigated graphically (Fig. 5 ). There appears to be a positive correlation between AUC and increase in platelet count from baseline.
અ．Safety
Eltrombopag was safe and well tolerated when administered as single doses up to 100 mg and repeat doses over 10 days up to 75 mg in healthy Japanese males.
There were 5 kinds of adverse events(6 episodes) reported in 5 of the 16 subjects in Study A. In Study B, there were 5 kinds of adverse events(6 episodes) reported in 6 of the 30 subjects who received eltrombopag. No events after administration of placebo were reported in the 12 subjects in Study B ( Table 4 ).
All of these events except for acute pharyngitis after a single dose of placebo were mild and recovered without any treatment. There was no apparent relationship between the dose level of eltrombopag and adverse event incidence.
Discussion
Although absolute bioavailability data for eltrombopag are not available, following a single oral administration of eltrombopag 75 mg as a solution to healthy non-Japanese, absorption of drug related material is estimated to be at least 52％ based on urinary excretion and metabolites elimination in faeces 11) . Eltrombopag is extensively metabolised via a number of pathways that include cleavage, oxidation and conjugation with glucuronic acid, glutathione or cysteine 11) . Based on in vitro data, CYP1A2 and CYP2C8 are responsible for the oxidative metabolism and UGT1A1 and UGT1A3 are responsible for the glucronidation 11) . In addition, in vitro studies have identified eltrombopag as a substrate of the BCRP transporter, but not a substrate of OATP1B1 nor Pgp Non-Japanese：Same parameters are calculated using repeat dose data from 10 days repeat doses with non-Japanese males(placebo and 5-75 mg)using the same method as Study B. transporters 11, 12) . The pharmacokinetics of eltrombopag in healthy Japanese males was investigated with single doses of eltrombopag 30-100 mg in Study A, where dose proportionality of exposure(Cmax and AUC)was confirmed over this dose range. Evaluation of the proportion of AUC extrapolated suggested it was necessary to extend the blood-sampling time beyond 72 hours after dosing to adequately evaluate the terminal elimination phase of eltrombopag in plasma. Based on these results, in Study B a 5 day washout period was set between the single dose and the start of the repeat dose phase, and plasma eltrombopag concentrations were determined for up to 120 hours after both the single dose and last dose in the repeat dose phase.
Confirmation that steady state was reached within 7 days of starting the repeat dose phase was obtained by analysis of the slope of trough concentrations over time. The elimination half life after single dose was calculated to be 30-32 hours and is consistent with attaining the steady state within 7 days of starting dosing(i.e. within 5 half-lives). The Rs value after 10days repeat dosing of eltrombopag 25-75 mg was 1.1-1.2, showing that eltrombopag has predictable and time-invariant pharmacokinetics on repeat dosing.
In Study A, the AUC values after single oral doses of 50 mg and 75 mg administered in the fasted state were 2.0 and 2.3 times higher than previously reported results in the fasted state in non-Japanese subjects 13) . Though AUC0−∞ in Study B was calculated from longer sampling duration than in Study A and the non-Japanese study, the exposures after single doses of 50 mg and 75 mg obtained in Study B were slightly lower than those obtained in Study A but were still 1.5-1.7 times higher than the AUC values obtained in the comparable study in non-Japanese under the same determination method 13) . The AUC at steady state after repeat doses of 75 mg obtained in Study B was 2.0 times higher than that obtained in a study in non-Japanese using a capsule formulation of eltrombopag 2) . Of note, relative bioavailability of capsule formulation was 15％ higher than that of tablet 13) . In a population pharmacokinetic analysis using the results of a clinical study conducted in non-Japanese chronic ITP patients, an ethnic difference in exposure was observed between Asians who were principally of East Asian ancestry and non-Asians who were principally of European ancestry. The AUC in Asian was 1.87 fold higher than that of non-Asian ITP patients, consistent with the finding in the present study. Based on the population PK analysis, Asian 
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Adverse Event(n, ％) ancestry was associated with a 33.5％ lower plasma ／ eltrombopag CL／F, which translates to a 50％ higher plasma eltrombopag exposure 14) . With respect to the ethnic difference between Asians and non-Asians noted in the population PK, a difference in body weight is one of the significant covariates for eltrombopag pharmacokinetic parameters. The AUC values, calculated using the same method as in the present study following 50 mg and 75 mg eltrombopag administration in the fasted state in the non-Japanese subjects were 65.2 and 76.9 ／ mg・hr／mL, respectively, compared with 101 and 130 ／ mg・hr／mL at the same doses in Japanese subjects. The mean body weights of the non-Japanese subjects at the two dose levels were 70.3 kg and 76.0 kg compared with 63.4 and 65.3 kg for the Japanese subjects 13) . While this may have contributed, it did not fully explain the ethnic difference in exposure. The results of population PK analysis in Japanese and non-Japanese healthy volunteers and ITP patients clearly show that bodyweight is one of the significant ／ covariates for eltrombopag CL／F. However other factors(East Asian or other races, concomitantly administered corticosteroid or not, male or female, healthy or ITP patients)are also significant covari-／ ates for CL／F even when body weight is already ／ included in the CL／F estimation model 14) . As eltrombopag is a substrate of BCRP as well as several drug metabolizing enzymes such as CYP1A2, CYP2C8, UGT1A1 and UGT1A3 11, 12) , the activities of which can differ between East Asian and Western populations, it is unlikely that any one factor will be solely responsible for the inter-ethnic differences observed in eltrombopag pharmacokinetics. In practice, the factors responsible for the observed inter-ethnic difference in eltrombopag pharmacokinetics have not yet been defined.
In Study A, the urinary eltrombopag concentrations were analysed but were below the detection limit in most subjects. This result is consistent with the finding in a study in non-Japanese subjects that following a single oral dose of 14 C-eltrombopag(75 mg), 59％ of the dose was excreted via the feces and 31％ via the urine, but of the drug related material in the urine none was detected as unchanged eltrombopag 11) .
The mean maximum platelet count increase observed in Study B(54％ in the 25-mg group, 72％ in the 50-mg group and 90％ in the 75-mg group)were greater than the mean maximum increases observed after 10-days repeat dose of eltrombopag 30 mg, 50 mg and 75 mg to healthy non-Japanese adults, in whom the increases were 24.1％, 42.9％ and 50.4％, respectively 2) . Figure 5 shows the relationship between platelet count increase and AUC is comparable among Japanese and non-Japanese subjects. The higher increases in platelet count in Japanese than in non-Japanese subjects is consistent with the interethnic difference observed in systemic eltrombopag exposure. It was thus suggested that a similar platelet count-increasing effect of eltrombopag might be obtained at lower doses in Japanese than in non-Japanese subjects. Based on these results, the initial dose of eltrombopag recommended for East Asians is half of that recommended for non-Asians 11, 12) . The adverse events reported after administration of eltrombopag in the 2 studies conducted in healthy Japanese adults were all mild and the subjects recovered without any treatment. Although the eltrombopag exposure in Japanese was significantly higher than in non-Japanese, the incidence of adverse events in Japanese was not higher than was observed in healthy non-Japanese subjects 2, 13) . In 1 subject, the maximum platelet count after ／ repeat doses of 25 mg was 59.8×10 4 ／mL, and platelet count took 64 days after the last dose to return to the ／ reference range. The AUC value(31.4 mg・hr／mL) after repeat dose in this subject was not particularly high compared with the other subjects. As platelet life is approximately 7-10 days 15) and the peak platelet count in this subject was less than twice the upper limit of the normal range, the reason why platelet count did not return more rapidly to the normal range ／ is unclear. There were no abnormal subjective／ objective findings in this subject. The safety of eltrombopag was confirmed in single dose up to 100 mg and following 10-days repeat doses up to 75 mg.
The present study evaluated the safety, pharmacokinetics and pharmacodynamics of eltrombopag in healthy Japanese males for the first time. The pharmacokinetics and pharmacodynamics data show exposure and increase in platelet count that are higher compared to previously reported results in non-Japanese. The finding led to a lower starting dose of eltrombopag in Japanese.
